MA52492A - Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés - Google Patents

Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés

Info

Publication number: MA52492A
Authority: MA; Morocco
Prior art keywords: inhibitor compounds; use processes; related preparation; rip1 inhibitor; rip1
Prior art date: 2018-05-03

Application number

MA052492A

Other languages

English (en)

Other versions

MA52492B1 (fr

Inventor

Yan Chen

Ihab Darwish

Esteban Masuda

Vanessa Taylor

Jiaxin Yu

Original Assignee

Rigel Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-05-03

Filing date

2019-05-02

Publication date

2021-03-10

2019-05-02 Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc

2021-03-10 Publication of MA52492A publication Critical patent/MA52492A/fr

2023-09-27 Publication of MA52492B1 publication Critical patent/MA52492B1/fr

Links

102100021009 Cytochrome b-c1 complex subunit Rieske, mitochondrial Human genes 0.000 title 1
101000643956 Homo sapiens Cytochrome b-c1 complex subunit Rieske, mitochondrial Proteins 0.000 title 1
101001099199 Homo sapiens RalA-binding protein 1 Proteins 0.000 title 1
101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Rheumatology (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

MA52492A 2018-05-03 2019-05-02 Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés MA52492B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201862666452P	2018-05-03	2018-05-03
PCT/US2019/030473 WO2019213445A1 (fr)	2018-05-03	2019-05-02	Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés

Publications (2)

Publication Number	Publication Date
MA52492A true MA52492A (fr)	2021-03-10
MA52492B1 MA52492B1 (fr)	2023-09-27

Family

ID=66554488

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA52492A MA52492B1 (fr)	2018-05-03	2019-05-02	Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés

Country Status (38)

Country	Link
US (3)	US10975064B2 (fr)
EP (1)	EP3788045B1 (fr)
JP (1)	JP7379467B2 (fr)
KR (1)	KR102823195B1 (fr)
CN (1)	CN112384510B (fr)
AU (1)	AU2019262142B2 (fr)
BR (1)	BR112020022423A2 (fr)
CA (1)	CA3099018A1 (fr)
CL (1)	CL2020002840A1 (fr)
CO (1)	CO2020015153A2 (fr)
CR (1)	CR20200582A (fr)
CY (1)	CY1126152T1 (fr)
DK (1)	DK3788045T3 (fr)
DO (1)	DOP2020000197A (fr)
EA (1)	EA202092581A1 (fr)
EC (1)	ECSP20077518A (fr)
ES (1)	ES2947446T3 (fr)
FI (1)	FI3788045T3 (fr)
HR (1)	HRP20230909T1 (fr)
HU (1)	HUE062277T2 (fr)
IL (1)	IL278416B2 (fr)
JO (1)	JOP20200277B1 (fr)
LT (1)	LT3788045T (fr)
MA (1)	MA52492B1 (fr)
MD (1)	MD3788045T2 (fr)
MX (1)	MX2020011622A (fr)
MY (1)	MY205388A (fr)
PE (1)	PE20210414A1 (fr)
PH (1)	PH12020551848A1 (fr)
PL (1)	PL3788045T3 (fr)
PT (1)	PT3788045T (fr)
RS (1)	RS64418B1 (fr)
SG (1)	SG11202010913PA (fr)
SI (1)	SI3788045T1 (fr)
SM (1)	SMT202300203T1 (fr)
UA (1)	UA128160C2 (fr)
WO (1)	WO2019213445A1 (fr)
ZA (1)	ZA202007487B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MD3788045T2 (ro) *	2018-05-03	2023-09-30	Rigel Pharmaceuticals Inc	Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora
HRP20231381T1 (hr) *	2018-05-03	2024-03-01	Rigel Pharmaceuticals, Inc.	Spojevi inhibitori rip1 i postupci za njihovo dobivanje i upotrebu
CA3149926A1 (fr)	2019-09-06	2021-03-11	Yan Chen	Composes inhibiteurs de rip1 et leurs procedes de fabrication et d'utilisation
WO2021046515A1 (fr)	2019-09-06	2021-03-11	Board Of Regents, The University Of Texas System	Inhibiteurs de la protéine kinase i interagissant avec le récepteur pour le traitement d'une maladie
JP7493586B2 (ja)	2019-09-06	2024-05-31	ライジェルファーマシューティカルズ，インコーポレイテッド	Ｒｉｐ１阻害化合物ならびにそれを作製および使用するための方法
IL291665B2 (en)	2019-09-27	2025-07-01	Univ Texas	Inhibitors of receptor interacting protein kinase i for the treatment of disease
SI4055021T1 (sl) *	2019-11-07	2026-02-27	Rigel Pharmaceuticals, Inc.	Heterociklične spojine, ki inhibirajo rip1
BR112022010082A2 (pt) *	2019-11-26	2022-08-30	Univ Texas	Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, uso do composto e uso da composição farmacêutica
AR121717A1 (es)	2020-04-02	2022-06-29	Rigel Pharmaceuticals Inc	Inhibidores de rip1k
TWI840311B (zh)	2020-07-01	2024-04-21	美商雷傑製藥公司	Rip1k抑制劑
JP7775288B2 (ja) *	2020-08-18	2025-11-25	ハチメドリミテッド	ピリミジノン化合物およびその使用
AR125587A1 (es)	2021-03-11	2023-08-02	Rigel Pharmaceuticals Inc	Inhibidores heterocíclicos de la quinasa de rip1
WO2022237890A1 (fr) *	2021-05-14	2022-11-17	中国医药研究开发中心有限公司	Composé à cycle fusionné du type azépine et son utilisation pharmaceutique
CN115894489A (zh) *	2021-09-22	2023-04-04	中国药科大学	一种受体相互作用蛋白激酶1的抑制剂及其制备方法、应用
EP4422621A4 (fr) *	2021-10-27	2025-08-27	Merck Sharp & Dohme Llc	Inhibiteurs de ripk1 spirotricycliques et leurs procédés d'utilisation
KR20230100646A (ko) *	2021-12-24	2023-07-05	제일약품주식회사	Ripk1 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물
TW202400588A (zh) *	2022-02-28	2024-01-01	香港商維泰瑞隆（香港）生物科技有限公司	Ｒｉｐ１調製劑、其製備及用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4921475A (en)	1983-08-18	1990-05-01	Drug Delivery Systems Inc.	Transdermal drug patch with microtubes
US5087240A (en)	1983-08-18	1992-02-11	Drug Delivery Systems Inc.	Transdermal drug patch with conductive fibers
US4738851A (en)	1985-09-27	1988-04-19	University Of Iowa Research Foundation, Inc.	Controlled release ophthalmic gel formulation
US5163899A (en)	1987-03-20	1992-11-17	Drug Delivery Systems Inc.	Transdermal drug delivery system
US5312325A (en)	1987-05-28	1994-05-17	Drug Delivery Systems Inc	Pulsating transdermal drug delivery system
GB8804164D0 (en)	1988-02-23	1988-03-23	Tucker J M	Bandage for administering physiologically active compound
US4882150A (en)	1988-06-03	1989-11-21	Kaufman Herbert E	Drug delivery system
US5008110A (en)	1988-11-10	1991-04-16	The Procter & Gamble Company	Storage-stable transdermal patch
US5088977A (en)	1988-12-21	1992-02-18	Drug Delivery Systems Inc.	Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en)	1989-09-28	1996-05-28	Alcon Laboratories, Inc.	Topical ophthalmic pharmaceutical vehicles
DK0431519T3 (da)	1989-12-04	1994-07-04	Searle & Co	System til transdermal indgivelse af albuterol
US5077033A (en)	1990-08-07	1991-12-31	Mediventures Inc.	Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
JP2594486B2 (ja)	1991-01-15	1997-03-26	アルコンラボラトリーズインコーポレイテッド	局所的眼薬組成物
US5352456A (en)	1991-10-10	1994-10-04	Cygnus Therapeutic Systems	Device for administering drug transdermally which provides an initial pulse of drug
DE69228827T2 (de)	1991-12-18	1999-10-21	Minnesota Mining And Mfg. Co., Saint Paul	Mehrschichtige sperrstrukturen
ATE132381T1 (de)	1992-01-29	1996-01-15	Voelkl Franz Ski	Ballspielschläger, insbesondere tennisschläger
IL114193A (en)	1994-06-20	2000-02-29	Teva Pharma	Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es)	1994-08-08	1997-08-01	Cusi Lab	Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
IT1283911B1 (it)	1996-02-05	1998-05-07	Farmigea Spa	Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en)	1997-01-29	1998-09-01	Bausch & Lomb Incorporated	Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en)	1998-04-07	2001-07-17	Alcon Manufacturing, Ltd.	Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en)	1998-05-22	2001-03-06	Collagenesis, Inc.	Compound delivery using rapidly dissolving collagen film
EP2192838A4 (fr)	2007-08-15	2011-07-27	Harvard College	Inhibiteurs hétérocycliques de la nécroptose
TWI637951B (zh) *	2013-02-15	2018-10-11	英商葛蘭素史克智慧財產發展有限公司	作為激酶抑制劑之雜環醯胺類
US20160024098A1 (en)	2013-03-15	2016-01-28	President And Fellows Of Harvard College	Hybrid necroptosis inhibitors
CN106573006A (zh) *	2014-08-21	2017-04-19	葛兰素史密斯克莱知识产权发展有限公司	作为药物的rip1激酶抑制剂杂环酰胺
BR112017017411A2 (pt)	2015-02-13	2018-04-03	Glaxosmithkline Ip Dev Ltd	Formas cristalinas de (s)-5-benzil-n-(5-metil-4-oxo- 2,3,4,5-tetraidrobenzo[b][1,4]oxazepin-3-il)-4h-1,2,4- triazol-3-carboxamida
EP3317269B1 (fr)	2015-07-02	2022-09-21	F. Hoffmann-La Roche AG	Lactames bicycliques en tant qu'inhibiteurs de la protéine kinase 1 interagissant avec des récepteurs pour le traitment par ex. de maladies inflammatoires
ES2885474T3 (es)	2015-10-13	2021-12-13	Inst Nat Sante Rech Med	Derivados de sibirilina para la utilización en la prevención y/o tratamiento de trastornos asociados a la necroptosis celular
AU2016340527B2 (en)	2015-10-23	2020-09-17	Takeda Pharmaceutical Company Limited	Heterocyclic compound
US10961258B2 (en)	2015-12-21	2021-03-30	Glaxosmithkline Intellectual Property Development Limited	Heterocyclic amides as kinase inhibitors
IL287136B2 (en)	2016-02-05	2023-09-01	Denali Therapeutics Inc	Receptor inhibitors - interacting with protein kinase 1
WO2018073193A1 (fr)	2016-10-17	2018-04-26	F. Hoffmann-La Roche Ag	Lactames de pyridone bicycliques et leurs méthodes d'utilisation
US11072607B2 (en)	2016-12-16	2021-07-27	Genentech, Inc.	Inhibitors of RIP1 kinase and methods of use thereof
US20200062735A1 (en)	2017-02-27	2020-02-27	Glaxosmithkline Intellectual Property Development Limited	Heterocyclic amides as kinase inhibitors
HRP20231381T1 (hr)	2018-05-03	2024-03-01	Rigel Pharmaceuticals, Inc.	Spojevi inhibitori rip1 i postupci za njihovo dobivanje i upotrebu
MD3788045T2 (ro)	2018-05-03	2023-09-30	Rigel Pharmaceuticals Inc	Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora
TW202019913A (zh)	2018-06-26	2020-06-01	中國科學院上海有機化學研究所	細胞壞死抑制劑及其製備方法和用途
WO2020088194A1 (fr)	2018-11-02	2020-05-07	中国科学院上海药物研究所	Amide hétérocyclique inhibant la kinase rip1 et ses applications
CA3149926A1 (fr)	2019-09-06	2021-03-11	Yan Chen	Composes inhibiteurs de rip1 et leurs procedes de fabrication et d'utilisation
JP7493586B2 (ja)	2019-09-06	2024-05-31	ライジェルファーマシューティカルズ，インコーポレイテッド	Ｒｉｐ１阻害化合物ならびにそれを作製および使用するための方法
SI4055021T1 (sl) *	2019-11-07	2026-02-27	Rigel Pharmaceuticals, Inc.	Heterociklične spojine, ki inhibirajo rip1
AR121717A1 (es)	2020-04-02	2022-06-29	Rigel Pharmaceuticals Inc	Inhibidores de rip1k

2019
- 2019-05-02 MD MDE20210214T patent/MD3788045T2/ro unknown
- 2019-05-02 FI FIEP19724662.2T patent/FI3788045T3/fi active
- 2019-05-02 SI SI201930550T patent/SI3788045T1/sl unknown
- 2019-05-02 LT LTEPPCT/US2019/030473T patent/LT3788045T/lt unknown
- 2019-05-02 AU AU2019262142A patent/AU2019262142B2/en active Active
- 2019-05-02 WO PCT/US2019/030473 patent/WO2019213445A1/fr not_active Ceased
- 2019-05-02 CN CN201980045150.5A patent/CN112384510B/zh active Active
- 2019-05-02 US US16/402,103 patent/US10975064B2/en active Active
- 2019-05-02 EP EP19724662.2A patent/EP3788045B1/fr active Active
- 2019-05-02 DK DK19724662.2T patent/DK3788045T3/da active
- 2019-05-02 IL IL278416A patent/IL278416B2/en unknown
- 2019-05-02 HR HRP20230909TT patent/HRP20230909T1/hr unknown
- 2019-05-02 JP JP2021510283A patent/JP7379467B2/ja active Active
- 2019-05-02 EA EA202092581A patent/EA202092581A1/ru unknown
- 2019-05-02 BR BR112020022423-5A patent/BR112020022423A2/pt unknown
- 2019-05-02 RS RS20230648A patent/RS64418B1/sr unknown
- 2019-05-02 ES ES19724662T patent/ES2947446T3/es active Active
- 2019-05-02 SG SG11202010913PA patent/SG11202010913PA/en unknown
- 2019-05-02 UA UAA202007282A patent/UA128160C2/uk unknown
- 2019-05-02 MA MA52492A patent/MA52492B1/fr unknown
- 2019-05-02 HU HUE19724662A patent/HUE062277T2/hu unknown
- 2019-05-02 MX MX2020011622A patent/MX2020011622A/es unknown
- 2019-05-02 PE PE2020001796A patent/PE20210414A1/es unknown
- 2019-05-02 SM SM20230203T patent/SMT202300203T1/it unknown
- 2019-05-02 PL PL19724662.2T patent/PL3788045T3/pl unknown
- 2019-05-02 KR KR1020207034544A patent/KR102823195B1/ko active Active
- 2019-05-02 MY MYPI2020005729A patent/MY205388A/en unknown
- 2019-05-02 CR CR20200582A patent/CR20200582A/es unknown
- 2019-05-02 PT PT197246622T patent/PT3788045T/pt unknown
- 2019-05-02 CA CA3099018A patent/CA3099018A1/fr active Pending
2020
- 2020-11-02 CL CL2020002840A patent/CL2020002840A1/es unknown
- 2020-11-02 DO DO2020000197A patent/DOP2020000197A/es unknown
- 2020-11-03 PH PH12020551848A patent/PH12020551848A1/en unknown
- 2020-11-03 JO JOJO/P/2020/0277A patent/JOP20200277B1/ar active
- 2020-12-01 ZA ZA2020/07487A patent/ZA202007487B/en unknown
- 2020-12-01 EC ECSENADI202077518A patent/ECSP20077518A/es unknown
- 2020-12-01 CO CONC2020/0015153A patent/CO2020015153A2/es unknown
2021
- 2021-03-23 US US17/210,261 patent/US11919890B2/en active Active
2023
- 2023-07-25 CY CY20231100349T patent/CY1126152T1/el unknown
2024
- 2024-02-05 US US18/432,727 patent/US20240217958A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2019213445A1 (fr)	2019-11-07
IL278416A (fr)	2020-12-31
MA52492B1 (fr)	2023-09-27
EA202092581A1 (ru)	2021-04-08
IL278416B1 (en)	2023-08-01
PH12020551848A1 (en)	2021-06-28
JP2021523225A (ja)	2021-09-02
PT3788045T (pt)	2023-06-26
KR20210006407A (ko)	2021-01-18
EP3788045B1 (fr)	2023-05-31
HUE062277T2 (hu)	2023-10-28
CN112384510A (zh)	2021-02-19
MD3788045T2 (ro)	2023-09-30
HRP20230909T1 (hr)	2023-12-08
JP7379467B2 (ja)	2023-11-14
FI3788045T3 (fi)	2023-06-28
ES2947446T3 (es)	2023-08-09
JOP20200277B1 (ar)	2024-04-18
DOP2020000197A (es)	2021-04-30
CN112384510B (zh)	2025-06-13
US20210214347A1 (en)	2021-07-15
RS64418B1 (sr)	2023-09-29
CY1126152T1 (el)	2023-11-15
DK3788045T3 (da)	2023-06-26
US20190337934A1 (en)	2019-11-07
CL2020002840A1 (es)	2021-04-16
SG11202010913PA (en)	2020-12-30
CA3099018A1 (fr)	2019-11-07
SI3788045T1 (sl)	2023-07-31
BR112020022423A2 (pt)	2021-02-02
SMT202300203T1 (it)	2023-09-06
AU2019262142A1 (en)	2020-11-26
MX2020011622A (es)	2021-02-17
AU2019262142B2 (en)	2024-11-21
ECSP20077518A (es)	2021-03-31
PE20210414A1 (es)	2021-03-04
KR102823195B1 (ko)	2025-06-20
CO2020015153A2 (es)	2021-03-08
US10975064B2 (en)	2021-04-13
MY205388A (en)	2024-10-19
ZA202007487B (en)	2023-01-25
IL278416B2 (en)	2023-12-01
PL3788045T3 (pl)	2023-10-09
CR20200582A (es)	2021-04-14
LT3788045T (lt)	2023-06-26
US20240217958A1 (en)	2024-07-04
UA128160C2 (uk)	2024-04-24
EP3788045A1 (fr)	2021-03-10
US11919890B2 (en)	2024-03-05
JOP20200277A1 (ar)	2020-11-03

Publication	Publication Date	Title
MA52492A (fr)	2021-03-10	Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés
MA52488A (fr)	2021-03-10	Composés inhibiteurs de rip1 et leurs procédés de fabrication et d'utilisation
MA56032A (fr)	2022-04-06	Composés, compositions et procédés d'utilisation
EP3768267A4 (fr)	2022-04-20	Composés inhibiteurs de kinase, compositions et procédés d'utilisation
EP3675848A4 (fr)	2021-03-10	Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
MA54953A (fr)	2021-12-22	Composés, compositions et procédés
EP3675847A4 (fr)	2021-01-06	Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
EP3781563A4 (fr)	2021-02-24	Inhibiteurs d'hpk1, procédé de préparation et utilisation associés
EP3370715A4 (fr)	2019-05-15	Composés chimères de ciblage de protéolyse et procédés de préparation et d'utilisation de ceux-ci
MA48942A (fr)	2020-04-08	Composés thérapeutiques, compositions et procédés d'utilisation associés
EP3782998A4 (fr)	2021-12-08	Composé de pyrrolotriazine substitué, composition pharmaceutique et utilisation associées
MA54148A (fr)	2022-02-09	Mélanges et compositions comprenant de la 5-fluoro-4-imino-3-méthyl-1-tosyl-3,4-dihydropyrimidin-2-one et leurs procédés d'utilisation
MA49560A (fr)	2020-05-20	Composés cétoniques bicycliques et leurs procédés d'utilisation
MA54959A (fr)	2021-12-22	Composés, compositions et procédés
EP3790552A4 (fr)	2022-06-15	Compositions de combinaison comprenant des composés de bisfluoroalkyle-1,4-benzodiazépinone et leurs procédés d'utilisation
EP3887402A4 (fr)	2022-10-26	Plaquettes utilisées comme agents d'administration
MA52098A (fr)	2021-01-27	Agonistes de ppar, composés, compositions pharmaceutiques et leurs procédés d'utilisation
EP3964518C0 (fr)	2026-01-28	Inhibiteur de cd73, son procédé de préparation et son utilisation
MA55532A (fr)	2022-02-09	Composés de neuréguline-4 et procédés d'utilisation
EP3920977A4 (fr)	2022-10-19	Procédés améliorés d'angiographie
EP3853352A4 (fr)	2022-08-10	Plaque de puits fonctionnalisée, procédés de préparation et d'utilisation de celle-ci
EP3911355A4 (fr)	2022-06-01	Lubricines recombinantes, compositions et procédés d'utilisation de celles-ci
EP3935037A4 (fr)	2023-03-22	Utilisation de composés de 8,9-dihydrocannabidiol
EP3500546A4 (fr)	2020-01-08	Propenylamines et leurs procédés de préparation et d'utilisation
EP3619193A4 (fr)	2021-01-06	Composés amino-aryl-benzamide et leurs procédés d'utilisation